Episode Details
Back to Episodes
Daily Roundup | Taiho and Cullinan Stop Lung Cancer Trial Early — Data Too Good to Stay Blinded
Published 1 month ago
Description
Taiho and Cullinan halt their first-line EGFR exon 20 lung cancer trial early with zipalertinib — the data was too good to stay blinded — raising the bar for J&J's Rybrevant, AstraZeneca and Dizal's Zegfrovy, and ArriVent's firmonertinib. Also: Definium's DT120 separates from placebo by 5.4 points in Phase 3 generalized anxiety from a single dose of pharmaceutical-grade LSD — and the stock gives back a third of its pop. Plus Karyopharm faces default on a September loan payment as it files Xpovio in myelofibrosis, and Eli Lilly escalates its fight against the retatrutide black market. Visit us at thepharmacloseout.com.